Matthew Ethan J, Verma Kritin K, Paulger Brent
Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA.
Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.
Cureus. 2025 Mar 31;17(3):e81539. doi: 10.7759/cureus.81539. eCollection 2025 Mar.
This case report describes a 66-year-old female patient with a history of treatment-resistant chronic cutaneous lupus and discoid lupus (DL) for 25 years. The patient failed traditional antimalarial therapies for cutaneous lupus and other systemic and topical treatments, including azathioprine, mycophenolate mofetil, methotrexate, and dapsone. The patient was started on deucravacitinib at a daily dose of 6 mg and showed resolution of active lesions at five months, with post-inflammatory hypopigmentation at sites of previous lesions. The patient showed clinical resolution at eight months after starting deucravacitinib. Deucravacitinib is an allosteric inhibitor of TYK2, an enzyme within the JAK/STAT pathway, and may represent a novel therapy in the treatment of cutaneous lupus through the inhibition of type I interferon signal propagation. Further studies of deucravacitinib, including longitudinal evaluation, should be conducted to determine effectiveness within this patient population.
本病例报告描述了一名66岁女性患者，患有难治性慢性皮肤性狼疮和盘状狼疮（DL）达25年。该患者针对皮肤性狼疮的传统抗疟治疗以及其他全身和局部治疗均告失败，这些治疗包括硫唑嘌呤、霉酚酸酯、甲氨蝶呤和氨苯砜。患者开始服用每日剂量为6毫克的氘可来昔替尼，五个月时活动性皮损消退，先前皮损部位出现炎症后色素减退。患者在开始服用氘可来昔替尼八个月后临床症状消退。氘可来昔替尼是JAK/STAT途径中的一种酶TYK2的变构抑制剂，通过抑制I型干扰素信号传播，可能代表一种治疗皮肤性狼疮的新型疗法。应开展包括纵向评估在内的关于氘可来昔替尼的进一步研究，以确定其在该患者群体中的有效性。
